The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

Background: In untreated ALK-positive non-small cell lung cancer no randomized controlled trials (RCTs) are available directly comparing next-generation ALK-inhibitors. We conducted a sensitivity analysis using the likelihood of being helped or harmed (LHH). Methods: Phase III trials comparing ALK-i...

Full description

Saved in:
Bibliographic Details
Main Authors: Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Cancer Treatment and Research Communications
Subjects:
ALK-inhibitors
Alectinib
Lorlatinib
Brigatinib
Ensartinib
LHH
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294224000546
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294224000546

Similar Items